I-FDA-Iyavunyelwa kusukela ngo-2009
I-Savella (i-milnacipran) yayivunyelwe i-FDA ngoJanuwari 2009 njengokwelashwa kwe- fibromyalgia . Ngaleso sikhathi, kwakuyisidakamizwa esisha kumakethe yase-US. Ngenxa yokuthi intsha, ayikho ifomu generic etholakalayo okwamanje.
I-Savella iyi-inhibitor ye-serotonin-norepinephrine, noma i-SNRI. Ngencazelo, ama-SNRIs anesifo sokucindezeleka. Kodwa-ke, i-Savella ayivunyelwe ukucindezeleka e-US Kuze kube manje, i-fibromyalgia iyona kuphela ukusetshenziswa okuvunyelwe kulezi zizwe.
Noma kunjalo, i-milnacipran ithengiswa eYurophu ngaphansi kwamagama eziningana zamagama, kuhlanganise noDalcipran, i-Ixel nabanye. Izidakamizwa zaseMilnacipran zitholakale ezimakethe zangaphandle iminyaka engaphezu kweyishumi futhi zivunyelwe ukucindezeleka emazweni angaphezu kwangu-50.
Okushiwo ngu-Savella
U-Savella ukwandisa amazinga we-neurotransmitters serotonin ne- norepinephrine , engaba khona kubantu abane fibromyalgia. Lokhu kubeka ekilasini elifanayo njengoCymbalta , e-FDA-evunyelwe i-fibromyalgia, ubuhlungu obukhulu, ukucindezeleka, kanye nezinye izimo.
Kodwa-ke, i-Savella, kubikwa ukuthi ukwandisa i-norepinephrin ngaphezu kwe-serotonin.
Isicelo Esisha seDrug for Savella, esithunyelwe ngoDisemba ka-2007, sifaka idatha kusuka kuvivinyo ezimbili lweSigaba III olubandakanya iziguli ezingaphezu kuka-2 000. Le nkampani ithi idatha yabonisa ukuthi uSapella wayesebenza kahle kune-placebo futhi wayebekezelela kahle. Kwakungekho ukufa phakathi nezifundo futhi iningi lemiphumela emibi lachazwa njengomnene ukulinganisa.
Izifundo zamuva zisekele imiphumela yokuqala, kubonisa ukuthuthukiswa okuphawulekayo kwezimpawu, kufaka phakathi ubuhlungu, ukukhathala nokulala. Nokho, ukubuyekezwa kuka-2015 kuphelile ukuthi kusebenza kuphela ngamaphesenti angama-40 alabo abayithathayo. (Lokhu kufana nezindleko zokusebenza ze-Cymbalta kanye nezinye izidakamizwa ze-fibromyalgia ezivunyelwe i-FDA, i- Lyrica .)
I-Savella Isilinganiso
Izinga eliphakanyisiwe lika-Savella liyi-100 mg noma i-200 mg ngosuku, ihlukaniswe ngamanani amabili. Kuyinto evamile ukuqala esilinganisweni esincane futhi kancane kancane usebenze kuze kube semali egcwele.
Akuphephile ukuyeka ngokungazelelwe ukuthatha i-Savella. Uma ufuna ukuphuma kwesidakamizwa, qiniseka ukuthi ukhuluma nodokotela wakho mayelana nenqubo yokuhlanza efanele .
I-Savella Side Effects
Njengazo zonke izidakamizwa, i-Savella ingabangela ezinye imiphumela emibi emibi. Akuwona wonke umuntu owenza, kodwa kufanele uqaphele ukuthi yiziphi lapho uqala ukuthatha lesi sidakamizwa. Eminye yemiphumela emibi ingaba yingozi.
Thola usizo lwezokwelapha ngokushesha uma unesinye sezibonakaliso ezilandelayo:
- ukusabela okweqile kakhulu (ukuxubha, ukuphika umquba, ukuphefumula ubunzima, ukuqina kwesifuba, ukuvuvukala kobuso, izindebe noma ulimi)
- ukuziphatha okungavamile
- izitofu zamanzi noma zamnyama
- ukudideka
- umchamo omnyama
- ukujuluka ngokweqile
- ukuphelelwa amandla
- ukushaya kwenhliziyo okusheshayo noma okungavamile
- umkhuhlane
- izikhukhula
- umphimbo ophikelela oqhubekayo
- izindlu
- ukulahlekelwa kokusebenzisana
- izinkinga zememori
- ubuhlungu besisu noma ubuthakathaka
- ukukhathazeka, ukucindezeleka, ukuhlaselwa kwesibindi, ukuhlukumezeka, ukucindezela, ukuthukuthela, ukuthukuthela, ukuphumula noma ukungakwazi ukuhlala
- izitebe eziluhlaza
- obomvu, ukuvuvukala, isikhumba esikhanyayo noma esikhumba
- ukuhlukunyezwa
- isifo esibuhlungu noma esiqhubekayo noma isiyezi
- i-nausea eqinile noma ephikelela
- ukuhlanza noma uhudo
- inkinga enkulu noma ephikisayo yokulala
- ubuhlungu besisu
- imicabango yokuzibulala noma ukuziphatha
- ukuthuthumela
- ukukhathazeka ukuchama
- ukulimaza okungavamile noma ukuphaphaza
- Izinguquko ezingavamile noma ezinzima ezingqondweni noma ezingqondweni
- ubuthakathaka obungavamile
- ukuphuzika kwesikhumba noma amehlo (i-jaundice)
Imiphumela emibi engadingi ukunakekelwa kwezokwelapha ihlanganisa:
- ukuqotshwa
- ukwehlisa isifiso sobulili noma ukusebenza
- isiyezi
- umlomo owomile
- ikhanda
- izikhukhula ezishisayo
- ukujuluka okukhulu
- ukulahlekelwa ukudla
- isiyaluyalu
- inkathazo yokulala
Kungenzeka ukuthi izidakamizwa zisebenzisane kabi. Khuluma nodokotela wakho kanye / noma wemithi mayelana nazo zonke izimo zakho zezokwelapha nokusebenzisana okungenzeka nezinye izidakamizwa ongase uthathe.
Ingabe i-Savella Ikulungele?
Asisoze sazi ukuthi izidakamizwa (izi) zizosisiza kuze sizame. Uma ufuna ukuzama u-Savella, khuluma nodokotela wakho mayelana nenzuzo nokuqapha futhi wenze isinqumo ndawonye.
Imithombo:
U-Ahmed M, et al. Umagazini wemithi yokulala emtholampilo. 2015 Sep 14. pii: jc-00381-14. Imiphumela ye-milnacipran ekuphazamiseni ubuthongo ku-fibromyalgia: ukutadisha kwe-crobosover okungahleliwe, kabili-mpumputhe, okuyi-twobob, okuyi-two-way.
Cording M, et al. Idatha yeCochrane yokubuyekeza okuhlelekile. 2015 Okthoba 20; 10: CD008244. I-Milnacipran yokuzwa ubuhlungu e-fibromyalgia kubantu abadala.
Mease PJ, Palmer RH, Wang Y. Journal of rheumatology emitholampilo. 2014 Jun; 20 (4): 195-202. Imiphumela ye-milnacipran ezintweni ezihlukahlukene zokukhathala kanye nobuhlobo bokukhathala ebuhlungu nasemsebenzini: ukuhlaziywa okuhloswe kwe-3 fibromyalgia.
Staud R, et al. Umbhalo wezinhlungu. 2015 Aug; 16 (8): 750-9. Imiphumela ye-milnacipran ebuhlungu obungokwelashwa kanye ne-hyperalgesia yeziguli ezine-fibromyalgia: imiphumela yesilingo esilawulwa ngokungahleliwe esingamaviki ayisithupha.
Vitton O, et al. I-psychopharmacology yabantu. 2004 Oct; 19 Ukusekela 1: S27-35. Isivivinyo esilawulwa yi-placebo-blind blind-blinded of milnacipran ekwelapheni kwe-fibromyalgia.